These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 18199717)

  • 1. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
    Jin Z; Mori Y; Yang J; Sato F; Ito T; Cheng Y; Paun B; Hamilton JP; Kan T; Olaru A; David S; Agarwal R; Abraham JM; Beer D; Montgomery E; Meltzer SJ
    Oncogene; 2007 Sep; 26(43):6332-40. PubMed ID: 17452981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer.
    Jin Z; Olaru A; Yang J; Sato F; Cheng Y; Kan T; Mori Y; Mantzur C; Paun B; Hamilton JP; Ito T; Wang S; David S; Agarwal R; Beer DG; Abraham JM; Meltzer SJ
    Clin Cancer Res; 2007 Nov; 13(21):6293-300. PubMed ID: 17975140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.
    Jin Z; Wang L; Zhang Y; Cheng Y; Gao Y; Feng X; Dong M; Cao Z; Chen S; Yu H; Zhao Z; Zhang X; Liu J; Mori Y; Fan X; Meltzer SJ
    Sci Rep; 2013 Oct; 3():2838. PubMed ID: 24088706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.
    Jin Z; Wang L; Cao Z; Cheng Y; Gao Y; Feng X; Chen S; Yu H; Wu W; Zhao Z; Dong M; Zhang X; Liu J; Fan X; Mori Y; Meltzer SJ
    BMC Cancer; 2014 May; 14():345. PubMed ID: 24885118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
    Jin Z; Cheng Y; Olaru A; Kan T; Yang J; Paun B; Ito T; Hamilton JP; David S; Agarwal R; Selaru FM; Sato F; Abraham JM; Beer DG; Mori Y; Shimada Y; Meltzer SJ
    Int J Cancer; 2008 Nov; 123(10):2331-6. PubMed ID: 18729198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
    Jin Z; Zhao Z; Cheng Y; Dong M; Zhang X; Wang L; Fan X; Feng X; Mori Y; Meltzer SJ
    Cancer; 2013 Oct; 119(20):3604-9. PubMed ID: 23893879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
    Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
    Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis.
    Jin Z; Mori Y; Hamilton JP; Olaru A; Sato F; Yang J; Ito T; Kan T; Agarwal R; Meltzer SJ
    Cancer; 2008 Jan; 112(1):43-9. PubMed ID: 17999418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Eads CA; Lord RV; Kurumboor SK; Wickramasinghe K; Skinner ML; Long TI; Peters JH; DeMeester TR; Danenberg KD; Danenberg PV; Laird PW; Skinner KA
    Cancer Res; 2000 Sep; 60(18):5021-6. PubMed ID: 11016622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
    Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
    Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis.
    Lee OJ; Schneider-Stock R; McChesney PA; Kuester D; Roessner A; Vieth M; Moskaluk CA; El-Rifai W
    Neoplasia; 2005 Sep; 7(9):854-61. PubMed ID: 16229808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
    Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
    Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
    Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.